2096 Aktienübersicht Die Simcere Pharmaceutical Group Limited beschäftigt sich mit der Forschung, Entwicklung, Herstellung und dem Verkauf von pharmazeutischen Produkten für Händler und Apothekenketten und andere Arzneimittelhersteller in China. Mehr Details
Belohnungen Risikoanalyse Bei unseren Risikoprüfungen wurden keine Risiken für 2096 festgestellt.
Alle Risikoprüfungen anzeigen Erfassen Sie Ihre Gedanken, Links und Unternehmenseinschätzung
Simcere Pharmaceutical Group Limited Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Simcere Pharmaceutical Group Historische Aktienkurse Aktueller Aktienkurs HK$6.74 52-Wochen-Hoch HK$7.70 52-Wochen-Tief HK$4.98 Beta 0.41 1 Monat Veränderung 0.60% 3 Monate Veränderung 0% 1 Jahr Veränderung 28.87% 3 Jahre Veränderung -18.99% 5 Jahre Veränderung n/a Veränderung seit IPO -38.62%
Aktuelle Nachrichten und Updates
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for Sim0505 (CDH6 Antibody-Drug Conjugate) Issued by the National Medical Products Administration Jan 06
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable Nov 21
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29 Weitere Updates anzeigen
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for Sim0505 (CDH6 Antibody-Drug Conjugate) Issued by the National Medical Products Administration Jan 06
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable Nov 21
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Aug 24
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
Now 22% overvalued Aug 03
Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing Jul 29
Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration Jul 17
Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug Jul 11
Co-Founder recently sold HK$1.2m worth of stock Jun 28
Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China Jun 25 Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024. Jun 20
Upcoming dividend of CN¥0.16 per share Jun 11
Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China Jun 01
Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong May 23
Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems May 01
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 26
Consensus revenue estimates fall by 14% Mar 22
Dividend of CN¥0.16 announced Mar 22 Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024
Consensus EPS estimates fall by 37% Mar 16
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China Mar 16
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration Mar 13
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500 Mar 12
Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023 Feb 20
Consensus EPS estimates fall by 35% Feb 20
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19 Jan 19
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets Jan 12
Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market Dec 29
Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Dec 27
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration Dec 04
Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration Nov 30
Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Oct 31
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration Oct 17
Co-Founder recently bought HK$1.2m worth of stock Aug 31
Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates Aug 28
Consensus revenue estimates fall by 22% Aug 28
First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022) Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 28
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 23
Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jul 01
Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jun 30
Co-Founder recently sold HK$710k worth of stock Jun 30
New minor risk - Insider selling Jun 23
Co-Founder recently sold HK$2.3m worth of stock Jun 21
Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023 Jun 16
Co-Founder recently bought HK$1.5m worth of stock Jun 15
Upcoming dividend of CN¥0.16 per share at 2.3% yield Jun 12
Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%? Jun 03
Co-Founder recently sold HK$3.1m worth of stock Apr 30
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 19
Investor sentiment improves as stock rises 15% Apr 13
Consensus revenue estimates fall by 13% Apr 11
Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically Apr 06
Now 23% undervalued Feb 06
Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration Jan 30
Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director Jan 19
Investor sentiment deteriorated over the past week Jan 19
Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration Jan 17
Now 24% undervalued Jan 17
Co-Founder recently bought HK$7.9m worth of stock Jan 11
Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096) Jan 10 Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023
Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration Dec 30
Now 20% undervalued Dec 30
Investor sentiment improved over the past week Dec 29
Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment Dec 21
Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment Dec 19
Investor sentiment deteriorated over the past week Dec 06
Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study Dec 03
Insufficient new directors Nov 16
Simcere Pharmaceutical Group Limited Announces Executive Changes Nov 10
Investor sentiment improved over the past week Nov 02
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application Oct 28
Investor sentiment improved over the past week Oct 14
First half 2022 earnings released: EPS: CN¥0.024 (vs CN¥0.21 in 1H 2021) Oct 01
Consensus EPS estimates fall by 20% Sep 07
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 07
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 06
First half 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1H 2021) Sep 01
Simcere Pharmaceutical Group Limited Announces Executive and Committee Changes Sep 01
Simcere Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 31, 2022 Aug 20
With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case Aug 16
Simcere Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022 Aug 02
Cosela, the World's First Comprehensive Myeloprotection Drug Against Chemotherapy Damage, Wins Approval in China Jul 19
Simcere Pharmaceutical Group Limited Announces Conditional Marketing of COSELA (Trilaciclib Hydrochloride for Injection) in China by the National Medical Products Administration Jul 14
Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18 Jun 27 Aktionärsrenditen 2096 HK Pharmaceuticals HK Markt 7D -1.6% 2.7% 2.9% 1Y 28.9% 5.7% 26.3%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: 2096 übertraf die Branche Hong Kong Pharmaceuticals , die im vergangenen Jahr eine Rendite von 5.7 erzielte.
Rendite vs. Markt: 2096 übertraf den Markt Hong Kong, der im vergangenen Jahr eine Rendite von 26.3 erzielte.
Preisvolatilität Is 2096's price volatile compared to industry and market? 2096 volatility 2096 Average Weekly Movement 6.1% Pharmaceuticals Industry Average Movement 4.9% Market Average Movement 6.4% 10% most volatile stocks in HK Market 13.8% 10% least volatile stocks in HK Market 3.0%
Stabiler Aktienkurs: 2096 hatte in den letzten 3 Monaten im Vergleich zum Hong Kong -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 2096Die wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen Die Simcere Pharmaceutical Group Limited beschäftigt sich mit der Forschung, Entwicklung, Herstellung und dem Verkauf von pharmazeutischen Produkten für Händler und Apothekenketten und andere Arzneimittelhersteller in China. Das Unternehmen konzentriert sich auf verschiedene therapeutische Bereiche, darunter Onkologie, zentrales Nervensystem, Autoimmunerkrankungen, Infektionsschutz, Herz-Kreislauf und andere. Zu den wichtigsten Produkten des Unternehmens gehören Sanbexin, eine konzentrierte Edaravon- und Dexborneol-Lösung zur Injektion; Endostar, eine rekombinante menschliche Endostatin-Injektion; ENWEIDA, eine Envafolimab-Injektion; COSELA, ein Trilaciclib-Hydrochlorid zur Injektion; Iremod, eine Iiguratimod-Tablette; und XIANNUOXIN, eine Simnotrelvir-Tablette/Ritonavir-Tablette.
Mehr anzeigen Simcere Pharmaceutical Group Limited's Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Simcere Pharmaceutical Group im Vergleich zum Marktanteil des Unternehmens? 2096 grundlegende Statistiken Marktanteil HK$16.70b Gewinn(TTM ) -HK$1.18b Umsatz(TTM ) HK$6.78b
2.5x Kurs-Umsatz-Verhältnis
-14.2x Kurs-Gewinn-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) 2096 Gewinn- und Verlustrechnung (TTM ) Einnahmen CN¥6.34b Kosten der Einnahmen CN¥1.45b Bruttogewinn CN¥4.88b Sonstige Ausgaben CN¥5.99b Umsatz -CN¥1.10b
Zuletzt gemeldete Gewinne
Jun 30, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) -0.44 Bruttomarge 77.05% Nettogewinnspanne -17.39% Schulden/Eigenkapital-Verhältnis 14.5%
Wie hat sich 2096 auf lange Sicht entwickelt?
Historische Performance und Vergleiche Dividenden
2.5% Aktuelle Dividendenrendite
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/02/07 14:59 Aktienkurs zum Tagesende 2025/02/07 00:00 Gewinne 2024/06/30 Jährliche Einnahmen 2023/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr .
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github .
Analysten-Quellen Simcere Pharmaceutical Group Limited wird von 16 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Sharon Shi BOCI Research Ltd. Shaojing Tong BofA Global Research Bo Yu China International Capital Corporation Limited
13 weitere Analysten anzeigen 
